Copyright
©The Author(s) 2021.
World J Clin Cases. Mar 26, 2021; 9(9): 2100-2109
Published online Mar 26, 2021. doi: 10.12998/wjcc.v9.i9.2100
Published online Mar 26, 2021. doi: 10.12998/wjcc.v9.i9.2100
Sodium channel blockers | Calcium channel modulators | |||||
Carbamazepine | Oxcarbazepine | Lidocaine, by iv | BLA | Pregabalin | Gabapentin | |
T max | Within 12 h | 4.5 h | 5 min | 1 h | 3 h | |
C max | 0.5-25 μg/mL | 31.5 μmol/L | 2-5 mg/lanalgesic use | 3.83-9.46 μg/mL | 2.7-2.99 mg/L | |
t1/2 | 25-65 h (single dose); 12-17 h (long-term oral) | 2 h; 9 h (MHD) | 10 min (single dose); 1.5-2 h (continuous infusion) | 4 h | 5-6.5 h | 6.5 h |
Bioavailability | 58%-85% | > 95% | 100% | 90% | 47%-60% | |
Effect-onset time | 8-72 h | 1-3 h | 5 min (onset); 1 h (maintain) | Within 30 min (acute toothache); 5 h (maintain); 1 wk (diabetic neuropathy) | 24-28 h (repeated administration); no capping effect | |
Metabolism | Liver | Liver | Liver (mainly) | Liver (less) | No metabolism in the body | |
Excretion | Kidney (72%); Feces (28%) | Kidney (> 95%) | Kidney (mainly) | Kidney (92-99%) excreted as drug prototype | Kidney (mainly) excreted as drug prototype |
- Citation: Xiao H, Ma K, Huang D, Liu XG, Liu TH, Liu Q, Liu GZ, Song T, Tao W, Wu DS, Wang YX, Yang XQ, Zhang XM, Liu H, Liu YQ. Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain. World J Clin Cases 2021; 9(9): 2100-2109
- URL: https://www.wjgnet.com/2307-8960/full/v9/i9/2100.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i9.2100